Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What is your diagnosis? Multiple sclerosis

D E Mathews1

  • 1VitreoRetinal Foundation, Memphis, Tennessee, USA.

Optometry Clinics : the Official Publication of the Prentice Society
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing a perioperative peer performance appraisal system.

AORN journal·2001
Same author

Complications of neodymium:YAG cyclophotocoagulation in the treatment of open-angle glaucoma.

Optometry and vision science : official publication of the American Academy of Optometry·1999
Same author

Use of ubiquitin fusions to augment protein expression in transgenic plants.

Plant physiology·1999
Same author

Clinical grand rounds. Idiopathic central serous chorioretinopathy.

Optometry clinics : the official publication of the Prentice Society·1996
Same author

Mechanistic aspects of tagetitoxin inhibition of RNA polymerase from Escherichia coli.

Biochemistry·1994
Same author

Adverse reactions during retinal fluorescein angiography.

Journal of the American Optometric Association·1994

Multiple sclerosis, a central nervous system demyelinating disease, often causes vision loss. Intravenous methylprednisolone is the recommended treatment for optic neuritis, barring contraindications.

Area of Science:

  • Neurology
  • Ophthalmology

Background:

  • Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating disease.
  • Ocular manifestations are common in MS, including vision loss and optomotor deficits.

Observation:

  • Ocular symptoms in MS require integrated treatment of both systemic and ocular disease.
  • Optic neuritis is a frequent neurological complication of MS.

Findings:

  • Current treatment protocols advocate for intravenous methylprednisolone as the primary therapy for optic neuritis in MS.
  • Methylprednisolone is recommended unless significant patient contraindications exist.

Implications:

  • Effective management of MS-related optic neuritis can preserve visual function.

Related Experiment Videos

  • Future research may explore immunomodulatory agents like interferon and cyclosporin for MS ocular complications.